ATE397621T1 - Hemmer der interaktion zwischen p53 und mdm2 - Google Patents

Hemmer der interaktion zwischen p53 und mdm2

Info

Publication number
ATE397621T1
ATE397621T1 AT97935511T AT97935511T ATE397621T1 AT E397621 T1 ATE397621 T1 AT E397621T1 AT 97935511 T AT97935511 T AT 97935511T AT 97935511 T AT97935511 T AT 97935511T AT E397621 T1 ATE397621 T1 AT E397621T1
Authority
AT
Austria
Prior art keywords
compounds
mdm2
interaction
human
inhibitors
Prior art date
Application number
AT97935511T
Other languages
English (en)
Inventor
David Lane
Volker Boettger
Angelika Boettger
Stephen Picksley
Heinz-Kurt Hochkeppel
Carlos Garcia-Echeverria
Patrick Chene
Pascal Furet
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614197.3A external-priority patent/GB9614197D0/en
Priority claimed from GBGB9707041.1A external-priority patent/GB9707041D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of ATE397621T1 publication Critical patent/ATE397621T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplifiers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT97935511T 1996-07-05 1997-07-04 Hemmer der interaktion zwischen p53 und mdm2 ATE397621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614197.3A GB9614197D0 (de) 1996-07-05 1996-07-05
GBGB9707041.1A GB9707041D0 (en) 1997-04-07 1997-04-07 Inhibitors of the interaction between p53 and mdm2

Publications (1)

Publication Number Publication Date
ATE397621T1 true ATE397621T1 (de) 2008-06-15

Family

ID=26309649

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97935511T ATE397621T1 (de) 1996-07-05 1997-07-04 Hemmer der interaktion zwischen p53 und mdm2

Country Status (8)

Country Link
EP (1) EP0958305B1 (de)
JP (1) JP2001500365A (de)
AT (1) ATE397621T1 (de)
AU (1) AU3847997A (de)
CA (1) CA2259149A1 (de)
DE (1) DE69738754D1 (de)
NZ (1) NZ333609A (de)
WO (1) WO1998001467A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
AU7238098A (en) * 1997-05-15 1998-12-08 Kyowa Hakko Kogyo Co. Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (de) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Phenoxyessigsäure- und Phenoxymethyltetrazolderivate mit Antitumoraktivität
ATE283915T1 (de) * 1998-05-26 2004-12-15 Inst Of Molecul & Cell Biology Polypeptide aus dem creb-bindenden protein und verwandten protein p-300 zur verwendung bei der transkriptionellen regulation
GB9819860D0 (en) * 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040038902A1 (en) 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
EP1633749A4 (de) 2003-02-13 2011-03-02 Us Gov Health & Human Serv Deazaflavinverbindungen und verfahren zu deren anwendung
CN107090025A (zh) 2003-11-05 2017-08-25 达纳-法伯癌症研究所股份有限公司 稳定的α螺旋肽及其用途
WO2005097820A1 (en) * 2004-04-06 2005-10-20 Korea Research Institute Of Bioscience And Biotechnology Peptides for inhibiting mdm2 function
WO2005114173A2 (en) * 2004-04-22 2005-12-01 Ortho-Mcneil Pharmaceuticals, Inc. Hdm2-inhibitor complexes and uses thereof
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CN102256615A (zh) 2009-01-14 2011-11-23 爱勒让治疗公司 拟肽大环化合物
EP2444105A4 (de) * 2009-06-16 2013-08-21 Univ Tokai Anti-gram-negativer bakterieller wirkstoff
WO2011005219A1 (en) * 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
EA201200321A1 (ru) 2009-08-26 2012-09-28 Новартис Аг Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012175487A1 (en) 2011-06-20 2012-12-27 Novartis Ag Cyclohexyl isoquinolinone compounds
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CN103974973A (zh) * 2011-11-09 2014-08-06 莫茨制药有限及两合公司 显示出缩短的生物学活性的神经毒素
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 ***交联的和硫醚交联的拟肽大环化合物
EP2855483B1 (de) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinonverbindungen
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
EP2948453B1 (de) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinonverbindungen als inhibitoren der p53/mdm2-interaktion
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP3004109A1 (de) 2013-05-27 2016-04-13 Novartis AG Imidazopyrrolidinonderivate und deren verwendung bei der behandlung einer krankheit
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
US9624247B2 (en) 2013-05-28 2017-04-18 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
JP2016537384A (ja) 2013-11-21 2016-12-01 ノバルティス アーゲー ピロロピロロン誘導体およびｂｅｔ阻害剤としてのその使用
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
EP3294318A4 (de) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
EP3724216A1 (de) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Durch stabilisiertes peptid vermittelter zielgerichteter proteinabbau
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109206474A (zh) * 2018-11-27 2019-01-15 青岛海洋生物医药研究院 一种线性肽合成方法
US20220153868A1 (en) * 2019-02-20 2022-05-19 Oncolyze, Inc Hdm2 antibody for use in treating cancer
CN112266407B (zh) * 2020-09-28 2023-05-12 宁夏医科大学总医院 特异结合p53蛋白的七肽、编码基因、制备方法及用途
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Also Published As

Publication number Publication date
AU3847997A (en) 1998-02-02
EP0958305B1 (de) 2008-06-04
JP2001500365A (ja) 2001-01-16
NZ333609A (en) 2000-08-25
EP0958305A2 (de) 1999-11-24
DE69738754D1 (de) 2008-07-17
CA2259149A1 (en) 1998-01-15
WO1998001467A2 (en) 1998-01-15

Similar Documents

Publication Publication Date Title
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
GEP20043363B (en) Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
ES2157994T3 (es) Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa.
AU3804500A (en) 2-amino-6-anilino-purines and their use as medicaments
MXPA02011303A (es) Nueva composicion farmaceutica.
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
DE60028970D1 (de) An her2 bindende peptidverbindungen
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
UA66865C2 (uk) Інденопіролокарбазоли, фармацевтична композиція, спосіб інгібування кіназної активності та спосіб лікування (варіанти)
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0958305

Country of ref document: EP

REN Ceased due to non-payment of the annual fee